ABBV Stock - AbbVie Inc.
Unlock GoAI Insights for ABBV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B |
| Gross Profit | $39.43B | $33.90B | $40.64B | $38.75B | $30.42B |
| Gross Margin | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% |
| Operating Income | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B |
| Net Income | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B |
| Net Margin | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% |
| EPS | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | HSBC Securities | Upgrade | Buy | $265 |
| November 13th 2025 | Scotiabank | Initiation | Sector Outperform | $280 |
| November 4th 2025 | DZ Bank | Downgrade | Hold | $237 |
| October 14th 2025 | Erste Group | Downgrade | Hold | - |
| October 1st 2025 | HSBC Securities | Downgrade | Hold | - |
| September 17th 2025 | Berenberg | Upgrade | Buy | $270 |
| August 12th 2025 | Piper Sandler | Resumed | Overweight | $231 |
| August 7th 2025 | Daiwa Securities | Upgrade | Outperform | $214 |
| May 14th 2025 | Citigroup | Downgrade | Neutral | $205 |
| April 22nd 2025 | Cantor Fitzgerald | Initiation | Overweight | $210 |
| December 10th 2024 | BofA Securities | Resumed | Neutral | $191 |
| December 5th 2024 | Daiwa Securities | Downgrade | Neutral | $180 |
| November 22nd 2024 | Leerink Partners | Upgrade | Outperform | $206 |
| November 15th 2024 | Wolfe Research | Initiation | Outperform | $205 |
| November 4th 2024 | Argus | Upgrade | Buy | - |
Earnings History & Surprises
ABBVEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 23, 2026 | — | — | — | — |
Q1 2026 | Jan 30, 2026 | $3.37 | — | — | — |
Q4 2025 | Oct 31, 2025 | $1.77 | $1.86 | +5.1% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $2.88 | $2.97 | +3.1% | ✓ BEAT |
Q2 2025 | Apr 25, 2025 | $2.38 | $2.46 | +3.4% | ✓ BEAT |
Q1 2025 | Jan 31, 2025 | $2.98 | $2.16 | -27.5% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $2.92 | $3.00 | +2.7% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $2.57 | $2.65 | +3.1% | ✓ BEAT |
Q2 2024 | Apr 26, 2024 | $2.26 | $2.31 | +2.2% | ✓ BEAT |
Q1 2024 | Feb 2, 2024 | $2.76 | $2.79 | +1.1% | ✓ BEAT |
Q4 2023 | Oct 27, 2023 | $2.86 | $2.95 | +3.1% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $2.79 | $2.91 | +4.3% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $2.44 | $2.46 | +0.8% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $3.54 | $3.60 | +1.7% | ✓ BEAT |
Q4 2022 | Oct 28, 2022 | $3.56 | $3.66 | +2.8% | ✓ BEAT |
Q3 2022 | Jul 29, 2022 | $3.31 | $3.37 | +1.8% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $3.14 | $3.24 | +3.2% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $3.29 | $3.31 | +0.6% | ✓ BEAT |
Q4 2021 | Oct 29, 2021 | $3.23 | $3.33 | +3.1% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $3.11 | $3.11 | 0.0% | = MET |
Latest News
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ Neutral'Several top drugmakers to lower US prices for some drugs-sources' - Reuters
📈 PositiveTrump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralCNBC Halftime Report Final Trades: AbbVie, Netflix, Microsoft, Twilio
➖ NeutralLENZ plunges after adverse event report on eye therapy
📉 NegativeMorgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $269
📈 PositiveHSBC Upgrades AbbVie to Buy, Raises Price Target to $265
📈 PositiveSkyrizi Receives CDA-AMC Conditional Reimbursement Recommendation For Moderately To Severely Active Ulcerative Colitis As AbbVie Concludes Letter Of Intent With Pan-Canadian Pharmaceutical Alliance
📈 PositiveAbbVie Secures FDA Approval For EPKINLY + R2, The Only Bispecific Antibody Combination Therapy Available For Patients With Relapsed Or Refractory Follicular Lymphoma After At Least One Line Of Systemic Therapy
📈 PositiveLive On CNBC, Josh Brown Hosts Segment Titled "Best Stocks In The Market: AbbVie; Amgen; Eli Lilly "
📈 PositiveAbbVie Announces New 6-Month 45mg LUPRON DEPOT Strength Receives Health Canada Approval For Treatment Of Advanced Prostate Cancer
📈 Positive'AbbVie cuts ties with Google-backed longevity company, lays off scientists'- STAT News
📉 NegativeAbbVie's Allergan To Present At American Society of Dermatologic Surgery (ASDS) Annual Meeting Nov. 13-16
➖ NeutralIronwood surges after Q3 beat; raised outlook for AbbVie-partnered Linzess
📈 PositiveUBS Maintains Neutral on AbbVie, Raises Price Target to $220
➖ NeutralIronwood wins FDA label expansion for bowel disease drug developed with AbbVie
📈 PositivePiper Sandler Reiterates Overweight on AbbVie, Raises Price Target to $289
📈 PositiveCalico Life Sciences Announces U.S. FDA Orphan Drug Designation For Investigational Treatment Of Autosomal Dominant Polycystic Kidney Disease
📈 PositiveCitigroup Maintains Neutral on AbbVie, Lowers Price Target to $235
➖ NeutralJP Morgan Maintains Overweight on AbbVie, Raises Price Target to $260
📈 PositiveFrequently Asked Questions about ABBV
What is ABBV's current stock price?
What is the analyst price target for ABBV?
What sector is AbbVie Inc. in?
What is ABBV's market cap?
Does ABBV pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ABBV for comparison